U.S., Aug. 9 -- ClinicalTrials.gov registry received information related to the study (NCT07111728) titled 'Intraoperative Margin Assessment in Breast Cancer With HSI-Raman' on July 28.
Brief Summary: Breast-conserving surgery (lumpectomy) aims to remove cancer while preserving healthy tissue, but up to 20% of patients require a second operation because cancer cells remain at the edge (margin) of the removed tissue. The Spectra-BREAST study evaluates a new optical device that combines hyperspectral imaging (HIS) and Raman spectroscopy (RS) with artificial-intelligence analysis to quickly assess the entire surface of excised breast specimens during surgery. By flagging areas at risk of positive margins in real time, the device may help surg...